Well that didn't last long.

MannKind (NASDAQ: MNKD) had its neutral rating reissued by analysts at Zacks. They currently have a $4.75 target price on the stock. Zacks’ analyst wrote, “MannKind’s first quarter 2013 net loss of $0.15 per share was narrower than the year-ago loss of $0.27 and the Zacks Consensus Estimate of a loss of $0.16. We expect investor focus to remain on Afrezza going forward. MannKind expects to present results on Afrezza from 2 late-stage studies (Affinity 1 and Affinity 2) in mid-August this year. The company plans to resubmit the NDA for Afrezza in late September or early October with a final decision expected in Apr/Mar 2014. However, we remain concerned about the company’s over dependence on Afrezza. Any setback related to the diabetes candidate will be catastrophic for MannKind. We see limited upside from current levels and retain our Neutral stance on the stock. Our target price is $4.75 per share.”

http://zolmax.com/stock-analysts-ratings-reiterations-for-may-14th-adsk-apa-becn-cake-clx-fio-gm-gmcr-gps-gsk/65605/